Alliance Pharma Plc (LON:APH) is the topic of conversation when Hardman & Co Analyst Dr Martin Hall joins DirectorsTalk. Martin explains how he believes the company has now grown into a very decent business, it’s main drivers, growth though 2018, the main attributes from an investment point of view and how the share price has performed.
Headquartered in Chippenham, UK, Alliance Pharma Plc commenced trading in 1998 and has been listed on AIM since 2003. Alliance has a strong track record of acquiring established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. It has sales in more than 100 countries either directly via its affiliates or through its selected network of distributor partners. Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Its analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Their focus is to raise companies’ profiles across the world with high-quality research, investor engagement programmes and advisory services.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; its FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
